George C Tsokos Selected Research

T-Cell Antigen Receptor-CD3 Complex

12/2008	Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells.
7/2003	Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George C Tsokos Research Topics

Disease

134	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2022 - 01/2002
45	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2004
27	Inflammation (Inflammations) 01/2022 - 11/2003
19	Ischemia 10/2017 - 06/2002
15	Lupus Nephritis 01/2022 - 07/2008
12	Rheumatoid Arthritis 07/2022 - 05/2002
11	Hemorrhage 01/2016 - 08/2004
10	Infections 01/2022 - 03/2005
9	Nephritis 10/2021 - 09/2009
9	Glomerulonephritis 01/2018 - 09/2008
9	Reperfusion Injury 10/2017 - 01/2004
8	Lung Injury 01/2021 - 02/2005
8	Wounds and Injuries (Trauma) 01/2020 - 03/2007
8	Mesenteric Ischemia 01/2017 - 12/2003
6	Arthritis (Polyarthritis) 07/2022 - 11/2003
6	Neoplasms (Cancer) 11/2018 - 10/2005
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 12/2015
5	Proteinuria 01/2021 - 02/2011
4	Experimental Arthritis 07/2022 - 11/2003
4	Psoriatic Arthritis 01/2021 - 12/2011
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 12/2011
4	COVID-19 01/2021 - 06/2020
4	Kidney Diseases (Kidney Disease) 01/2016 - 07/2010
4	Hemorrhagic Shock 01/2013 - 02/2007
4	Hypotension (Low Blood Pressure) 01/2013 - 02/2007
3	Fibrosis (Cirrhosis) 07/2022 - 07/2015
3	Rheumatic Diseases (Rheumatism) 12/2021 - 11/2003
3	Hypoxia (Hypoxemia) 04/2010 - 04/2003
2	Virus Diseases (Viral Diseases) 11/2021 - 05/2014
2	Acute Lung Injury 11/2020 - 06/2020
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/2020 - 06/2020
2	Lung Diseases (Lung Disease) 06/2020 - 05/2007
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

37	Interleukin-2 (IL2)IBA 01/2022 - 05/2002
34	AutoantibodiesIBA 01/2022 - 01/2004
31	Complement System Proteins (Complement)IBA 01/2022 - 01/2004
26	CytokinesIBA 07/2022 - 09/2005
23	Interleukin-17 (Interleukin 17)IBA 01/2022 - 12/2008
23	Proteins (Proteins, Gene)FDA Link 12/2018 - 10/2002
13	AntibodiesIBA 07/2022 - 01/2004
12	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2015 - 01/2002
11	CalciumIBA 10/2021 - 12/2003
11	Syk KinaseIBA 01/2021 - 03/2007
10	Antigen-Antibody Complex (Immune Complex)IBA 01/2020 - 10/2012
9	AntigensIBA 01/2022 - 09/2005
9	Cyclic AMP Response Element ModulatorIBA 01/2021 - 12/2011
9	zeta chain antigen T cell receptor (TCR zeta chain)IBA 11/2005 - 01/2002
8	Transcription Factors (Transcription Factor)IBA 01/2021 - 02/2007
7	Messenger RNA (mRNA)IBA 11/2012 - 06/2002
6	Interleukin-23 (Interleukin 23)IBA 01/2021 - 09/2009
6	Pharmaceutical PreparationsIBA 06/2020 - 08/2010
6	Immunoglobulin G (IgG)IBA 04/2016 - 04/2005
5	Calcium-Calmodulin-Dependent Protein Kinase Type 4IBA 07/2022 - 10/2012
5	KN 93IBA 07/2022 - 02/2011
5	Biomarkers (Surrogate Marker)IBA 10/2021 - 11/2004
5	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 05/2002
5	CD55 Antigens (Decay Accelerating Factor)IBA 01/2013 - 09/2007
5	Caspase 3 (Caspase-3)IBA 09/2007 - 12/2003
4	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 10/2018
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 05/2011
4	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 02/2008
4	AutoantigensIBA 01/2017 - 09/2003
4	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 07/2013 - 11/2005
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2012 - 06/2010
3	Calcium-Calmodulin-Dependent Protein KinasesIBA 10/2021 - 12/2011
3	Monoclonal AntibodiesIBA 01/2021 - 09/2005
3	LigandsIBA 01/2021 - 05/2014
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2021 - 09/2007
3	Interferon Type IIBA 12/2020 - 07/2011
3	fostamatinibIBA 11/2020 - 07/2015
3	EnzymesIBA 01/2020 - 05/2014
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 02/2011
3	RNA Splicing FactorsIBA 12/2018 - 01/2013
3	Signaling Lymphocytic Activation Molecule FamilyIBA 01/2017 - 01/2016
3	Complement C3 (C3 Complement)IBA 01/2017 - 09/2007
3	Complement Receptors (Complement Receptor)IBA 10/2015 - 12/2004
3	Therapeutic UsesIBA 11/2014 - 12/2003
3	Immunoglobulin M (IgM)IBA 12/2013 - 02/2009
3	Protein Isoforms (Isoforms)IBA 03/2013 - 05/2010
3	VaccinesIBA 02/2013 - 11/2006
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 12/2011 - 09/2004
3	Adenosine Triphosphate (ATP)IBA 09/2007 - 02/2005
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 09/2007 - 02/2005
3	geldanamycinIBA 09/2007 - 08/2004
2	GlutaminaseIBA 01/2022 - 11/2019
2	NAD (NADH)IBA 01/2022 - 01/2020
2	Biological ProductsIBA 12/2021 - 10/2005
2	Peptides (Polypeptides)IBA 01/2021 - 01/2017
2	Mucin-1 (CA 15-3 Antigen)IBA 01/2021 - 06/2020
2	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 01/2021 - 12/2018
2	Complement Inactivating AgentsIBA 01/2021 - 09/2005
2	Interleukin-12 (IL 12)IBA 01/2021 - 10/2018
2	InterferonsIBA 01/2021 - 12/2020
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2020 - 10/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 01/2018
2	nephrinIBA 01/2019 - 01/2018

Therapy/Procedure

13	Therapeutics 12/2021 - 05/2002
6	Resuscitation 01/2013 - 08/2004
3	Intravenous Injections 01/2013 - 07/2011
2	Fecal Microbiota Transplantation 07/2022 - 01/2022